Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock
Key facts
- Who runs it
- Northern Jiangsu People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 336 people, planned
- Started
- 2 Mar 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hydrocortisone plus Fludrocortisone
- Standard care
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- (1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h
Who cannot take part
- Systemic corticosteroid therapy within the last 3 months before septic shock
- High-dose steroid therapy
- Patients meeting any of the following conditions will be excluded:
- Known allergy to hydrocortisone or fludrocortisone
- Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting
- Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician)
- Immunosuppression
- Pregnant
- Refusal of the attending staff or patient family
- Current participation in another clinical trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.
The 2 groups in the trial
- Hydrocortisone plus FludrocortisoneTreatment being tested
Hydrocortisone: 200 mg per day administered by continuous intravenous infusion for up to 7 days or until ICU discharge, whichever occurs first. Fludrocortisone: 50 μg administered orally or via nasogastric tube once daily for up to 7 days or until ICU discharge, whichever occurs first.
- Standard careExisting treatment, for comparison
Patients will receive standard care for septic shock according to current international guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures, including the use of hydrocortisone at the discretion of the treating physician, but without fludrocortisone.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Initiation of Hydrocortisone and Fludrocortisone in Adult Patients With Septic Shock:A Prospective Randomized Controlled Clinical Trial
- Criteria questions
- Built from NCT07383103, who can take part
- Record updated
- 4 March 2026